P29.07 A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC

Abstract

Although PACIFIC regimen definitive concurrent chemoradiotherapy (CRT) followed by Durvalumab consolidation therapy is considered the standard of care for most of the stage III NSCLC patients, neoadjuvant immunotherapy combined with chemotherapy followed by surgery has shown the trend to be considered for some potentially resectable patients. The rationales for the neoadjuvant treatment are tumor regression effect before surgery, early eradication of micrometastasis. Recently we also find some clinical trials exploring the adding of 45 Gy in 25 fractions radiation to the combination of chemotherapy and immunotherapy neoadjuvant therapy and we could see the safety is the most concern, especially the pneumonitis incidence.